Comparative effects of dydrogesterone and medroxyprogesterone acetate in critical areas: The brain and the vessels

References

• Mendelsohn M E, Karas R H. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340: 1801–1811
   PubMed Web of Science ®Google Scholar
• Manson J E, Hsia J, Johnson K C, Rossouw J E, Assaf A R, Lasser N L, Trevisan M, Black H R, Heckbert S R, Detrano R, , The Women's Health Initiative Investigators, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349: 523–534
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. J Am Med Assoc 1998; 280: 605–613
   PubMed Web of Science ®Google Scholar
• Genazzani A R, Gambacciani M, Simoncini T. Estrogens and women's health: a scary or a fairy tale?. Gynecol Endocrinol 2004; 18: 175–178
   PubMed Web of Science ®Google Scholar
• The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2004; 291: 1701–1712
   PubMed Web of Science ®Google Scholar
• Miyagawa K, Rosch J, Stanczyk F, Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med 1997; 3: 324–327
   PubMed Web of Science ®Google Scholar
• Register T C, Adams M R, Golden D L, Clarkson T B. Conjugated equine estrogens alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys. Arterioscler Thromb Vasc Biol 1998; 18: 1164–1171
   PubMed Web of Science ®Google Scholar
• Adams M R, Kaplan J R, Manuck S B, Koritnik D R, Parks J S, Wolfe M S, Clarkson T B. Inhibition of coronary artery atherosclerosis by 17-βestradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis 1990; 10: 1051–1057
   PubMedGoogle Scholar
• Rosano G M, Webb C M, Chierchia S, Morgani G L, Gabraele M, Sarrel P M, de Ziegler D, Collins P. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Cardiol 2000; 36: 2154–2159
   PubMed Web of Science ®Google Scholar
• Wang M D, Wahlstrom G, Backstrom T. The regional brain distribution of the neurosteroids pregnenolone and pregnenolone sulfate following intravenous infusion. J Steroid Biochem Mol Biol 1997; 62: 299–306
   PubMed Web of Science ®Google Scholar
• Stoffel-Wagner B, Watzka M, Schramm J, Bidlingmaier F, Klingmuller D. Expression of CYP19 (aromatase) mRNA in different areas of the human brain. J Steroid Biochem Mol Biol 1999; 70: 237–241
   PubMedGoogle Scholar
• Baulieu E E. Neurosteroids: a new function in the brain. Biol Cell 1991; 71: 3–10
   PubMed Web of Science ®Google Scholar
• Baulieu E E. Neurosteroids: of the nervous system, by the nervous system, for the nervous system. Recent Prog Horm Res 1997; 52: 1–32
   PubMedGoogle Scholar
• Wolf O T, Neumann O, Hellhammer D H, Geiben A C, Strasburger C J, Dressendorfer R A, Pirke K M, Kirschbaum C. Effects of a two-week physiological dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly women and men. J Clin Endocrinol Metab 1997; 82: 2363–2367
   PubMed Web of Science ®Google Scholar
• Schumacher M, Coirini H, McEwen B S. Regulation of high-affinity GABAA receptors in the dorsal hippocampus by estradiol and progesterone. Brain Res 1989; 487: 178–183
   PubMedGoogle Scholar
• Palumbo M A, Salvestroni C, Gallo R, Guo A L, Genazzani A D, Artini P G, Petraglia F, Genazzani A R. Allopregnanolone concentration in hippocampus of prepubertal rats and female rats throughout estrous cycle. J Endocrinol Invest 1995; 18: 853–856
   PubMedGoogle Scholar
• Genazzani A R, Bernardi F, Stomati M, Monteleone P, Luisi S, Rubino S, Farzati A, Casarosa E, Luisi M, Petraglia F. Effects of estradiol and raloxifene analog on brain, adrenal and serum allopregnanolone content in fertile and ovariectomized female rats. Neuroendocrinology 2000; 72: 162–170
   PubMed Web of Science ®Google Scholar
• Genazzani A R, Palumbo M A, de Micheroux A A, Artini P G, Criscuolo M, Ficarra G, Guo A L, Benelli A, Bertolini A, Petraglia F, et al. Evidence for a role for the neurosteroid allopregnanolone in the modulation of reproductive function in female rats. Eur J Endocrinol 1995; 133: 375–380
   PubMed Web of Science ®Google Scholar
• Stomati M, Bernardi F, Luisi S, Puccetti S, Casarosa E, Liut M, Quirici B, Pieri M, Genazzani A D, Luisi M, et al. Conjugated equine estrogens, estrone sulphate and estradiol valerate oral administration in ovariectomized rats: effects on central and peripheral allopregnanolone and β-endorphin. Maturitas 2002; 43: 195–206
   PubMed Web of Science ®Google Scholar
• Genazzani A R, Stomati M, Bernardi F, Luisi S, Casarosa E, Puccetti S, Genazzani A D, Palumbo M, Luisi M. Conjugated equine estrogens reverse the effects of aging on central and peripheral allopregnanolone and β-endorphin levels in female rats. Fertil Steril 2004; 81(Suppl 1)757–766
   PubMedGoogle Scholar
• Bitran D, Shiekh M, McLeod M. Anxiolytic effect of progesterone is mediated by the neurosteroid allopregnanolone at brain GABAA receptors. J Neuroendocrinol 1995; 7: 171–177
   PubMed Web of Science ®Google Scholar
• Bitran D, Purdy R H, Kellogg C K. Anxiolytic effect of progesterone is associated with increases in cortical allopregnanolone and GABAA receptor function. Pharmacol Biochem Behav 1993; 45: 423–428
   PubMed Web of Science ®Google Scholar
• Frye C A, Bayon L E, Pursnani N K, Purdy R H. The neurosteroids, progesterone and 3α,5α-THP, enhance sexual motivation, receptivity, and proceptivity in female rats. Brain Res 1998; 808: 72–83
   PubMed Web of Science ®Google Scholar
• Corpechot C, Young J, Calvel M, Wehrey C, Veltz J N, Touyer G, Mouren M, Prasad V V, Banner C, Sjovall J, et al. Neurosteroids: 3α-hydroxy-5α-pregnan-20-one and its precursors in the brain, plasma, and steroidogenic glands of male and female rats. Endocrinology 1993; 133: 1003–1009
   PubMed Web of Science ®Google Scholar
• Bernardi F, Pluchino N, Pieri M, Begliuomini S, Lenzi E, Puccetti S, Casarosa E, Luisi M, Genazzani A R. Progesterone and medroxyprogesterone acetate effects on central and peripheral allopregnanolone and β-endorphin levels. Neuroendocrinology 2006; 83: 348–359
   PubMed Web of Science ®Google Scholar
• Rabe T, Kowald A, Ortmann J, Rehberger-Schneider S. Inhibition of skin 5α-reductase by oral contraceptive progestins in vitro. Gynecol Endocrinol 2000; 14: 223–230
   PubMed Web of Science ®Google Scholar
• Labrie F, Lagacè L, Drouin J. Direct and differential effects of sex steroids at the anterior pituitary level on LH and FSH secretion. Academic Press, London 1979
   Google Scholar
• Etgen A M, Karkanias G B. Estrogen regulation of noradrenergic signaling in the hypothalamus. Psychoneuroendocrinology 1994; 19: 603–610
   PubMed Web of Science ®Google Scholar
• Genazzani A R, Petraglia F, Facchinetti F, Grasso A, Alessandrini G, Volpe A. Steroid replacement treatment increases β-endorphin and β-lipotropin plasma levels in postmenopausal women. Gynecol Obstet Invest 1988; 26: 153–159
   PubMed Web of Science ®Google Scholar
• Genazzani A R, Petraglia F, Facchinetti F, Facchini V, Volpe A, Alessandrini G. Increase of proopiomelanocortin-related peptides during subjective menopausal flushes. Am J Obstet Gynecol 1984; 149: 775–779
   PubMed Web of Science ®Google Scholar
• Aleem F A, McIntosh T K. Menopausal syndrome: plasma levels of β-endorphin in post-menopausal women measured by a specific radioimmunoassay. Maturitas 1985; 7: 329–334
   PubMedGoogle Scholar
• Piva F, Limonta P, Dondi D, Pimpinelli F, Martini L, Maggi R. Effects of steroids on the brain opioid system. J Steroid Biochem Mol Biol 1995; 53: 343–348
   PubMed Web of Science ®Google Scholar
• Wardlaw S L, Wehrenberg W B, Ferin M, Antunes J L, Frantz A G. Effect of sex steroids on β-endorphin in hypophyseal portal blood. J Clin Endocrinol Metab 1982; 55: 877–881
   PubMed Web of Science ®Google Scholar
• Fox S R, Harlan R E, Shivers B D, Pfaff D W. Chemical characterization of neuroendocrine targets for progesterone in the female rat brain and pituitary. Neuroendocrinology 1990; 51: 276–283
   PubMedGoogle Scholar
• Dufourny L, Caraty A, Clarke I J, Robinson J E, Skinner D C. Progesterone-receptive β-endorphin and dynorphin B neurons in the arcuate nucleus project to regions of high gonadotropin-releasing hormone neuron density in the ovine preoptic area. Neuroendocrinology 2005; 81: 139–149
   PubMedGoogle Scholar
• Genazzani A R, Petraglia F, Bergamaschi M, Genazzani A D, Facchinetti F, Volpe A. Progesterone and progestins modulate β-endorphin concentrations in the hypothalamus and in the pituitary of castrated female rats. Gynecol Endocrinol 1987; 1: 61–69
   PubMedGoogle Scholar
• Szot P, Wilkinson C W, White S S, Leverenz J B, Greenup J L, Colasurdo E A, Peskind E R, Raskind M A. Chronic cortisol suppresses pituitary and hypothalamic peptide message expression in pigtailed macaques. Neuroscience 2004; 126: 241–246
   PubMedGoogle Scholar
• Mansour A, Khachaturian H, Lewis M E, Akil H, Watson S J. Anatomy of CNS opioid receptors. Trends Neurosci 1988; 11: 308–314
   PubMed Web of Science ®Google Scholar
• La Vecchia C, Decarli A, Franceschi S, Gentile A, Negri E, Parazzini F. Menstrual and reproductive factors and the risk of myocardial infarction in women under fifty-five years of age. Am J Obstet Gynecol 1987; 157: 1108–1112
   PubMed Web of Science ®Google Scholar
• Skafar D F, Xu R, Morales J, Ram J, Sowers J R. Clinical review 91: Female sex hormones and cardiovascular disease in women. J Clin Endocrinol Metab 1997; 82: 3913–3918
   PubMed Web of Science ®Google Scholar
• Herrington D M, Howard T D. From presumed benefit to potential harm – hormone therapy and heart disease. N Engl J Med 2003; 349: 519–521
   PubMed Web of Science ®Google Scholar
• Rossouw J E, Anderson G L, Prentice R L, LaCroix A Z, Kooperberg C, Stefanick M L, Jackson R D, Beresford S A, Howard B V, Johnson K C, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002; 288: 321–333
   PubMed Web of Science ®Google Scholar
• Hsia J, Langer R D, Manson J E, Kuller L, Johnson K C, Hendrix S L, Pettinger M, Heckbert S R, Greep N, Crawford S, for the Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: The Women's Health Initiative. Arch Intern Med 2006; 166: 357–365
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340: 115–126
   PubMed Web of Science ®Google Scholar
• Hansson G K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685–1695
   PubMed Web of Science ®Google Scholar
• Otsuki M, Saito H, Xu X, Sumitani S, Kouhara H, Kishimoto T, Kasayama S. Progesterone, but not medroxyprogesterone, inhibits vascular cell adhesion molecule-1 expression in human vascular endothelial cells. Arterioscler Thromb Vasc Biol 2001; 21: 243–248
   PubMed Web of Science ®Google Scholar
• Simoncini T, Mannella P, Fornari L, Caruso A, Varone G, Genazzani A R. In vitro effects of progesterone and progestins on vascular cells. Steroids 2003; 68: 831–836
   PubMed Web of Science ®Google Scholar
• Simoncini T, Mannella P, Fornari L, Caruso A, Willis M Y, Garibaldi S, Baldacci C, Genazzani A R. Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells. Endocrinology 2004; 145: 5745–5756
   PubMed Web of Science ®Google Scholar
• Liao J K. Endothelial nitric oxide and vascular inflammation. Endothelium, nitric oxide and atherosclerosis, J A Panza, R OI Cannon. Futura Publishing Co. Inc, Armonk, NY 1999; 119–132
   Google Scholar
• Kleinert H, Wallerath T, Euchenhofer C, Ihrig-Biedert I, Li H, Forstermann U. Estrogens increase transcription of the human endothelial NO synthase gene: analysis of the transcription factors involved. Hypertension 1998; 31: 582–588
   PubMed Web of Science ®Google Scholar
• Nilsen J, Brinton R D. Impact of progestins on estradiol-potentiation of the glutamate calcium response. Neuroreport 2002; 13: 825–830
   PubMedGoogle Scholar
• Nilsen J, Brinton R D. Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling. Proc Natl Acad Sci U S A 2003; 100: 10506–10511
   PubMed Web of Science ®Google Scholar
• Simoncini T, Genazzani A R. Non-genomic actions of sex steroid hormones. Eur J Endocrinol 2003; 148: 281–292
   PubMed Web of Science ®Google Scholar
• Brzozowski A M, Pike A C, Dauter Z, Hubbard R E, Bonn T, Engstrom O, Ohman L, Greene G L, Gustafsson J A, Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997; 389: 753–758
   PubMed Web of Science ®Google Scholar
• Simoncini T, Hafezi-Moghadam A, Brazil D P, Ley K, Chin W W, Liao J K. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000; 407: 538–541
   PubMed Web of Science ®Google Scholar
• Hafezi-Moghadam A, Simoncini T, Yang E, Limbourg F P, Plumier J C, Rebsamen M C, Hsieh C M, Chui D S, Thomas K L, Prorock A J, et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med 2002; 8: 473–479
   PubMed Web of Science ®Google Scholar
• Simoncini T, Rabkin E, Liao J K. Molecular basis of cell membrane estrogen receptor interaction with phosphatidylinositol 3-kinase in endothelial cells. Arterioscler Thromb Vasc Biol 2003; 23: 198–203
   PubMed Web of Science ®Google Scholar
• Simoncini T, Mannella P, Fornari L, Varone G, Caruso A, Genazzani A R. Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms. Endocrinology 2003; 144: 3449–3455
   PubMed Web of Science ®Google Scholar
• Gol M, Akan P, Dogan E, Karas C, Saygili U, Posaci C. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels. Maturitas 2006; 53: 252–259
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. New progestogens: a review of their effects in perimenopausal and postmenopausal women. Drugs Aging 2004; 21: 865–883
   PubMed Web of Science ®Google Scholar
• Hague S, MacKenzie I Z, Bicknell R, Rees M C. In-vivo angiogenesis and progestogens. Hum Reprod 2002; 17: 786–793
   PubMedGoogle Scholar
• Paris J M, Williams K J, Hermsmeyer K R, Delansorne R. Nomegestrol acetate and vascular reactivity: nonhuman primate experiments. Steroids 2000; 65: 621–627
   PubMedGoogle Scholar
• Williams J K, Delansorne R, Paris J. Estrogens, progestins, and coronary artery reactivity in atherosclerotic monkeys. J Steroid Biochem Mol Biol 1998; 65: 219–224
   PubMedGoogle Scholar
• Sorensen M B, Collins P, Ong P JL, Webb C M, Hayward C S, Asbury E A, Gatehouse P D, Elkington A G, Yang G Z, Kubba A, et al. Long-term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance. Circulation 2002; 106: 1646–1651
   PubMed Web of Science ®Google Scholar
• Koh K K, Jin D K, Yang S H, Lee S K, Hwang H Y, Kang M H, Kim W, Kim D S, Choi I S, Shin E K. Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women. Circulation 2001; 103: 1961–1966
   PubMed Web of Science ®Google Scholar
• McNeill A M, Zhang C, Stanczyk F Z, Duckles S P, Krause D N. Estrogen increases endothelial nitric oxide synthase via estrogen receptors in rat cerebral blood vessels: effect preserved after concurrent treatment with medroxyprogesterone acetate or progesterone. Stroke 2002; 33: 1685–1691
   PubMedGoogle Scholar
• Dinh H, Nathan L. Medroxyprogesterone acetate does not antagonize estrogen-induced increases in endothelium-dependent vasodilation: potential clinical implications. Fertil Steril 2002; 78: 122–127
   PubMedGoogle Scholar
• Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 2004; 47: 277–283
   PubMed Web of Science ®Google Scholar
• Zhang R, Min W, Sessa W C. Functional analysis of the human endothelial nitric oxide synthase promoter. Sp1 and GATA factors are necessary for basal transcription in endothelial cells. J Biol Chem 1995; 270: 15320–15326
   PubMedGoogle Scholar
• Garcia-Segura L M, Cardona-Gomez P, Naftolin F, Chowen J A. Estradiol upregulates Bcl-2 expression in adult brain neurons. Neuroreport 1998; 9: 593–597
   PubMedGoogle Scholar
• Chambliss K L, Shaul P W. Estrogen modulation of endothelial nitric oxide synthase. Endocr Rev 2002; 23: 665–686
   PubMed Web of Science ®Google Scholar
• McDonnell D P. Mining the complexities of the estrogen signaling pathways for novel therapeutics. Endocrinology 2003; 144: 4237–4240
   PubMedGoogle Scholar
• Li X, Wong J, Tsai S Y, Tsai M J, O'Malley B W. Progesterone and glucocorticoid receptors recruit distinct coactivator complexes and promote distinct patterns of local chromatin modification. Mol Cell Biol 2003; 23: 3763–3773
   PubMedGoogle Scholar
• Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules, risks, and benefits. Menopause 2002; 9: 6–15
   PubMed Web of Science ®Google Scholar
• Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 2005; 8(Suppl 1)3–63
   PubMed Web of Science ®Google Scholar
• Goetz R M, Thatte H S, Prabhakar P, Cho M R, Michel T, Golan D E. Estradiol induces the calcium-dependent translocation of endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 1999; 96: 2788–2793
   PubMed Web of Science ®Google Scholar
• Campagnoli C, Colombo P, De Aloysio D, Gambacciani M, Grazioli I, Nappi C, Serra G B, Genazzani A R. Positive effects on cardiovascular and breast metabolic markers of oral estradiol and dydrogesterone in comparison with transdermal estradiol and norethisterone acetate. Maturitas 2002; 41: 299–311
   PubMed Web of Science ®Google Scholar
• Mijatovic V, Kenemans P, Netelenbos J C, Peters-Muller E R, van Kamp G J, Voetberg G A, van de Weijer P H, van der Mooren M J. Oral 17β-estradiol continuously combined with dydrogesterone lowers serum lipoprotein(a) concentrations in healthy postmenopausal women. J Clin Endocrinol Metab 1997; 82: 3543–3547
   PubMed Web of Science ®Google Scholar
• Mijatovic V, Kenemans P, Netelenbos C, Jakobs C, Popp-Snijders C, Peters-Muller E R, van der Mooren M J. Postmenopausal oral 17β-estradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels. Fertil Steril 1998; 69: 876–882
   PubMed Web of Science ®Google Scholar
• Godsland I F, Crook D, Proudler A J, Stevenson J C. Hemostatic risk factors and insulin sensitivity, regional body fat distribution, and the metabolic syndrome. J Clin Endocrinol Metab 2005; 90: 190–197
   PubMed Web of Science ®Google Scholar
• Gaspard U J, Wery O J, Scheen A J, Jaminet C, Lefebvre P J. Long-term effects of oral estradiol and dydrogesterone on carbohydrate metabolism in postmenopausal women. Climacteric 1999; 2: 93–100
   PubMedGoogle Scholar
• de Kraker A T, Kenemans P, Smolders R G, Kroeks M V, van der Mooren M J. The effects of 17β-oestradiol plus dydrogesterone compared with conjugated equine oestrogens plus medroxyprogesterone acetate on lipids, apolipoproteins and lipoprotein(a). Maturitas 2004; 49: 253–263
   PubMed Web of Science ®Google Scholar
• Simoncini T, Caruso A, Giretti M S, Scorticati C, Fu X D, Garibaldi S, Baldacci C, Mannella P, Fornari L, Genazzani A R. Effects of dydrogesterone and of its stable metabolite, 20-α-dihydrodydrogesterone, on nitric oxide synthesis in human endothelial cells. Fertil Steril 2006; 86(Suppl 4)1235–1242
   PubMedGoogle Scholar